HTG Molecular Diagnostics, Inc.
HTGM · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.82 | 35.08 | 4.99 | 7.54 |
| FCF Yield | -5.19% | -0.46% | -0.45% | -0.37% |
| EV / EBITDA | -17.25 | -192.31 | -208.02 | -292.27 |
| Quality | ||||
| ROIC | -151.07% | -68.38% | -61.89% | -47.45% |
| Gross Margin | 28.18% | 54.02% | 53.31% | 53.60% |
| Cash Conversion Ratio | 0.85 | 0.96 | 0.78 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | -9.36% | -22.59% | -26.47% | 9.17% |
| Free Cash Flow Growth | -7.45% | -2.43% | 5.92% | -26.03% |
| Safety | ||||
| Net Debt / EBITDA | 0.37 | -0.11 | 0.54 | -0.22 |
| Interest Coverage | -24.31 | -16.74 | -19.11 | -19.80 |
| Efficiency | ||||
| Inventory Turnover | 5.03 | 2.06 | 2.68 | 7.02 |
| Cash Conversion Cycle | 61.70 | 115.90 | 80.94 | 44.05 |